Scientists / Our Scientists

Rodney Prell

Senior Fellow (Dev Sci), Safety Assessment

"It has been a privilege to work in Safety Assessment at Genentech, where we take patient safety as our highest priority."

Years at Genentech

Publications at Genentech

I received my PhD and postdoctoral training in immunotoxicology and cancer immunotherapy, respectively. I joined Genentech as a scientist/toxicologist in 2007 after six years of cancer immunotherapy pharmacology and toxicology research in small biotech in the San Francisco Bay Area. My initial responsibilities were mainly as a project team toxicologist where I designed and implemented non-clinical safety studies to support INDs through BLAs. I am currently a Staff Scientist/Toxicologist and Safety Assessment Therapeutic Area Lead for Cancer Immunology, where I have oversight for the safety assessment strategy for the Cancer Immunology portfolio. I am a Diplomat of the American Board of Toxicology (DABT) since 2004.

Featured Publication

Perspective on a Modified Developmental and Reproductive Toxicity Testing Strategy for Cancer Immunotherapy.

Int J Toxicol 2016 35(3): 263-273.

Prell, R.A., Halpern W.G. and Rao, G.

View Abstract

My focus area is the safety assessment of new molecular entities in cancer immunology. This area spans a wide variety of platforms and modalities and as such, requires flexible approaches for nonclinical safety to support first in human studies and appropriate first in human dose selection. We are exploring ways to improve the existing or develop novel nonclinical safety models support cancer immunology drug development.

Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody

JCI insight, ISSN: 23793708

Karin Staflin; Christina L. Zuch de Zafra; Leah Schutt; Vanessa Clark; Fiona Zhong; Maria Hristopoulos; Robyn Clark; Ji Li; Mary Mathieu; Xiaocheng Chen; Jennifer A. Johnston; Justin Low; Ryan Ybarra; Dionysos S. Slaga; Yang; Meric A. Ovacik; Noel Dybdal; Klara Totpal; Melissa Junttila; Diego Ellerman; Genee Y. Lee; Dennis; Prell; Teemu T. Junttila

View on Scopus

In vivo assessment of antibody-dependent enhancement of influenza B infection

Toxicological Sciences, ISSN: 10960929 10966080

Gautham K. Rao; Prell; Steven T. Laing; Stefanie C M Burleson; Allen Nguyen; Jacqueline McBride; Crystal Zhang; Daniel Sheinson; Wendy Halpern

View on Scopus

Resolution of unexpected pregnancy-related findings in a rat embryofetal development and toxicokinetic study of monoclonal antibodies specific for hCMV

Birth Defects Research, ISSN: 24721727

Paula Katavolos; Prell; Doris Zane; Rong Deng; Wendy Halpern

View on Scopus

Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3

Science Translational Medicine, ISSN: 19466242 19466234

Dionysos S. Slaga; Diego Ellerman; T. Noelle Lombana; Rajesh Vij; Ji Li; Maria Hristopoulos; Robyn Clark; Jennifer A. Johnston; Amy Shelton; Elaine Mai; Kapil Gadkar; Amy Lo; James T. Koerber; Klara Totpal; Prell; Genee Y. Lee; Christoph Spiess; Teemu T. Junttila

View on Scopus

Placental and fetal effects of onartuzumab, a Met/HGF signaling antagonist, when administered to pregnant cynomolgus monkeys

Toxicological Sciences, ISSN: 10960929 10966080

Prell; Noel Dybdal; Akihiro Arima; Yutaka Chihaya; Ihsan Nijem; Wendy Halpern

View on Scopus

An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia

Blood, ISSN: 15280020 00064971

Leong; Siddharth Sukumaran; Maria Hristopoulos; Klara Totpal; Shannon Stainton; Elizabeth Lu; Alfred Wong; Lucinda Tam; Robert J. Newman; Brian R. Vuillemenot; Diego Ellerman; Chen Gu; Mary Mathieu; Dennis; Allen Nguyen; Bing Zheng; Crystal Zhang; Genee Y. Lee; Yu-Waye Chu; Prell; Kedan Lin; Steven T. Laing; Andrew G. Polson

View on Scopus

Perspective on a Modified Developmental and Reproductive Toxicity Testing Strategy for Cancer Immunotherapy

International Journal of Toxicology, ISSN: 1092874X 10915818

Prell; Wendy Halpern; Gautham K. Rao

View on Scopus

Cytokine release assays: Current practices and future directions

Cytokine, ISSN: 10960023 10434666

Deborah Finco-Kent; Grimaldi; Fort; Walker; Kiessling; Wolf; Salcedo; Faggioni; Schneider; Ibraghimov; Scesney; Serna; Prell; Stebbings; Narayanan

View on Scopus

Nonclinical Development of Multi-targeting Biopharmaceuticals

Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics,

Prell; Donna W. Lee; Wendy Halpern; Anu V. Connor

View on Scopus

A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies

Cancer Cell, ISSN: 18783686 15356108

Gabriele Schaefer; Lauric Haber; Lisa Crocker; Steven Shia; Lily Shao; Dowbenko; Klara Totpal; Anne Wong; Chingwei V. Lee; Scott Stawicki; Robyn Clark; Carter Fields; Gail L. Phillips; Prell; Dimitry Danilenko; Yvonne Franke; Jean-Philippe Stephan; Jiyoung Hwang; Yan Wu; Jenny Bostrom; Mark X. Sliwkowski; Fuh; Eigenbrot

View on Scopus

Oregon State University, Ph.D. Toxicology Program (Immunotoxicology) – 1997
University of Wisconsin-Madison, Biochemistry, B.S. – 1989

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

We are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page, or call 1-877-436-3683. See the latest update on Actemra® (tocilizumab) supply here.

Rodney Prell

Senior Fellow (Dev Sci), Safety Assessment

Featured Publication

Perspective on a Modified Developmental and Reproductive Toxicity Testing Strategy for Cancer Immunotherapy.